Substance use disorders represent an escalating public health crisis worldwide, driving immense morbidity. Despite growing awareness, healthcare providers continue to face substantial obstacles because regulatory agencies have approved no targeted medications for stimulant use disorder. Consequently, clinicians rely primarily on behavioral therapies, which frequently yield variable retention rates. Emerging research now investigates whether novel formulations of established medications could bridge this critical therapeutic gap. In particular, Brixadi, an extended-release injectable buprenorphine formulation, has generated substantial interest among addiction specialists. While Brixadi currently holds approval exclusively for opioid use disorder, its unique pharmacodynamic properties may offer utility in psychostimulant addiction. Understanding these evolving mechanisms allows clinicians to appreciate new directions in addiction psychopharmacology.

The Neurobiology of Stimulant Use Disorder

Psychostimulants include illicit substances such as cocaine, methamphetamine, and various synthetic designer stimulants. Crucially, these agents share a fundamental mechanism within the central nervous system. They directly interact with presynaptic monoamine transporters, specifically targeting dopamine, norepinephrine, and serotonin systems. For example, cocaine blocks monoamine reuptake transporters, whereas amphetamines reverse normal transporter directionality. Consequently, excess neurotransmitters accumulate rapidly within the synaptic cleft. This sustained accumulation produces profound neurochemical stimulation across mesolimbic pathways. In particular, the surge in synaptic dopamine heavily reinforces repetitive consumption by overactivating reward circuits. Over time, persistent exposure reorganizes synaptic plasticity and recruits central stress pathways, including dynorphin and kappa opioid receptor systems. Because of this neurobiological cascade, patients experience severe dysphoria and psychological distress during stimulant cessation. Therefore, interrupting this reinforcement cycle represents an essential therapeutic objective. Current research seeks agents that can mitigate these distressing affective states without producing additional abuse liability.

Pharmacologic Profile of Brixadi and Opioid Receptors

Brixadi represents an innovative, extended-release subcutaneous formulation of buprenorphine designed to treat opioid use disorder. Unlike conventional sublingual preparations requiring daily administration, Brixadi utilizes a lipid-based crystalline depot delivery system. Following subcutaneous injection, the formulation transitions into a liquid crystal gel upon contact with interstitial fluid. As a result, the medication releases buprenorphine at a steady rate over weekly or monthly intervals. This pharmacokinetic profile avoids the peaks and troughs commonly observed with transmucosal formulations. Pharmacodynamically, buprenorphine possesses a unique receptor profile extending beyond standard opioid agonism. Specifically, buprenorphine functions as a partial agonist at mu-opioid receptors and a potent antagonist at kappa-opioid receptors. In addition, the compound demonstrates weak antagonist activity at delta-opioid receptors. The sustained plasma concentrations delivered by Brixadi ensure continuous receptor occupancy across extended periods. Consequently, this continuous receptor interaction modulates downstream dopamine release in the mesolimbic system. Clinicians recognize that such balanced modulation might attenuate aberrant reward signals without generating excessive euphoria.

Kappa Opioid Receptor Antagonism in Dysphoria and Cravings

The therapeutic rationale for using Brixadi in stimulant recovery rests primarily on its potent kappa opioid receptor antagonism. Chronic stimulant use recruits endogenous dynorphin, an opioid peptide that binds to kappa receptors throughout the amygdala and striatum. When dynorphin activates these receptors, it decreases dopamine release in the nucleus accumbens. Consequently, patients develop marked anhedonia, heightened stress sensitivity, and dysphoria during withdrawal. These negative emotional states frequently drive compulsive drug seeking as patients attempt to relieve severe psychological discomfort. Therefore, blocking kappa opioid receptors represents a rational strategy to normalize disrupted hedonic tone. By acting as a competitive antagonist at kappa receptors, buprenorphine effectively blunts dynorphin-mediated dysphoria and reduces stress-induced relapse vulnerability. Moreover, the extended-release profile of Brixadi maintains this receptor blockade without daily dosing compliance lapses. Preclinical models indicate that kappa receptor antagonism diminishes drug self-administration following periods of stress. In addition, this intervention helps restore balance to dysregulated stress response pathways. Thus, Brixadi might alleviate the intense affective distress that undermines abstinence.

Addressing Polysubstance Use Involving Opioids and Stimulants

Polysubstance use has become increasingly prevalent among patients presenting for substance use disorder treatment globally. In clinical practice, individuals frequently combine opioids with psychostimulants, such as fentanyl mixed with methamphetamine or cocaine. This co-use significantly magnifies morbidity, raises fatal overdose rates, and complicates psychiatric stabilization. Fortunately, Brixadi’s dual pharmacodynamic properties offer unique advantages for this vulnerable population. The partial mu-opioid receptor agonism prevents opioid withdrawal and blunts illicit opioid reward, while kappa receptor antagonism simultaneously targets stimulant-induced dysphoria. Furthermore, the weekly or monthly subcutaneous injection eliminates the daily burden of taking medication at home. This attribute is particularly beneficial for individuals with unstable housing or severe behavioral disorganization. Clinicians also note that long-acting injectables eliminate the risk of medication diversion and accidental exposure. As a result, treatment programs can maintain higher retention rates among patients who struggle with chaotic lifestyle patterns. Integrating long-acting buprenorphine into comprehensive addiction care plans may therefore provide a robust foundation for managing co-occurring substance use.

Clinical Considerations and Future Research Directions

Despite encouraging theoretical mechanisms and preclinical observations, physicians must approach this evolving intervention with appropriate clinical caution. Currently, regulatory agencies have approved Brixadi solely for moderate-to-severe opioid use disorder. Robust randomized controlled trials evaluating extended-release buprenorphine specifically in isolated stimulant use disorder have not yet concluded. Therefore, clinicians should not prescribe this medication off-label without careful consideration of patient risk factors. Buprenorphine remains an opioid partial agonist, which creates physical opioid dependence in opioid-naive individuals. Consequently, initiating Brixadi in a patient without pre-existing opioid tolerance could precipitate undesirable adverse effects or dependence. However, for patients presenting with combined opioid and stimulant use disorders, Brixadi represents a rational, evidence-supported intervention. Future investigations must explore whether pure kappa opioid receptor antagonists lacking mu-opioid activity can replicate these benefits in non-opioid-using populations. Meanwhile, comprehensive management of stimulant use disorder requires validated psychosocial modalities, including contingency management and cognitive behavioral therapy. Clinicians should monitor ongoing clinical trials as researchers evaluate novel therapeutic options.

Frequently Asked Questions

Is Brixadi currently approved for the treatment of stimulant use disorder?

No, regulatory authorities have not approved Brixadi for treating stimulant use disorder. The medication currently holds regulatory approval exclusively for treating moderate to severe opioid use disorder in adult patients. While promising preclinical research highlights the potential of kappa opioid receptor antagonism to reduce stimulant cravings, definitive clinical trials in humans are still lacking. Therefore, clinicians must continue utilizing behavioral interventions as the standard of care for isolated psychostimulant misuse.

How does kappa opioid receptor antagonism assist in stimulant addiction recovery?

Kappa opioid receptor antagonism counteracts the negative emotional states that typically emerge during stimulant withdrawal. Chronic stimulant abuse stimulates dynorphin release, which activates kappa receptors and precipitates severe dysphoria, anxiety, and anhedonia. By competitively blocking these receptors, buprenorphine alleviates profound psychological distress and stabilizes mesolimbic dopamine signaling. Consequently, this pharmacologic action mitigates stress-induced drug cravings, thereby reducing the likelihood of relapse during early recovery phases.

Can physicians safely administer Brixadi to patients without opioid tolerance?

Physicians should exercise extreme caution and avoid administering Brixadi to opioid-naive individuals. Because buprenorphine acts as a partial mu-opioid agonist, it can induce significant sedation, nausea, and physical opioid dependence in patients without baseline tolerance. In severe instances, it may even trigger respiratory depression. Therefore, Brixadi is primarily suited for patients with co-occurring opioid and stimulant use disorders rather than individuals presenting solely with isolated stimulant addiction.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Sawaya MF et al. Brixadi for Stimulant Use Disorder: Evolving Pharmacologic Considerations and Clinical Implications. Adv Ther. 2026 Sep 10. doi: 10.1007/s12325-026-03772-4. PMID: 42720725.
2. Lofwall MR, Walsh SL. A review of buprenorphine pharmacology and clinical applications. J Addict Med. 2014;8(5):315-326.
3. Raby WN, Coomaraswamy S, Levin FR. Buprenorphine for the treatment of cocaine dependence: a review. Am J Addict. 2014;23(5):427-436.
4. Substance Abuse and Mental Health Services Administration. Treatment of Stimulant Use Disorders. SAMHSA Publication No. PEP20-06-01-001. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2020.